Movatterモバイル変換

[0]ホーム
URL:

TJ392B - Fraction of copolymer-1 and method prodaction of it, composition for the treatment of multiple sclerosis, farmaceutical composition, method for the t reatment of multiple sclerosis. - Google Patents

Fraction of copolymer-1 and method prodaction of it, composition for the treatment of multiple sclerosis, farmaceutical composition, method for the t reatment of multiple sclerosis.

Info

Publication number
TJ392B
TJ392BTJ96000421ATJ96000421ATJ392BTJ 392 BTJ392 BTJ 392BTJ 96000421 ATJ96000421 ATJ 96000421ATJ 96000421 ATJ96000421 ATJ 96000421ATJ 392 BTJ392 BTJ 392B
Authority
TJ
Tajikistan
Prior art keywords
composition
multiple sclerosis
copolymer
prodaction
reatment
Prior art date
Application number
TJ96000421A
Inventor
Eliezer Konfino
Michael Sela
Dvora Teitelbaum
Ruth Arnon
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=26939072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TJ392(B)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & DevfiledCriticalYeda Res & Dev
Publication of TJ392BpublicationCriticalpatent/TJ392B/en

Links

Classifications

Landscapes

Abstract

The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
TJ96000421A1994-05-241995-05-23Fraction of copolymer-1 and method prodaction of it, composition for the treatment of multiple sclerosis, farmaceutical composition, method for the t reatment of multiple sclerosis.TJ392B (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US24803794A1994-05-241994-05-24
US34424894A1994-11-231994-11-23
PCT/US1995/006551WO1995031990A1 (en)1994-05-241995-05-23Copolymer-1 improvements in compositions of copolymers

Publications (1)

Publication NumberPublication Date
TJ392Btrue TJ392B (en)2004-10-13

Family

ID=26939072

Family Applications (1)

Application NumberTitlePriority DateFiling Date
TJ96000421ATJ392B (en)1994-05-241995-05-23Fraction of copolymer-1 and method prodaction of it, composition for the treatment of multiple sclerosis, farmaceutical composition, method for the t reatment of multiple sclerosis.

Country Status (30)

CountryLink
US (11)US5800808A (en)
EP (1)EP0762888B1 (en)
JP (2)JPH10500955A (en)
KR (1)KR100403750B1 (en)
CN (2)CN1174753C (en)
AT (1)ATE212857T1 (en)
AU (1)AU2602195A (en)
BR (2)BRPI9507758B1 (en)
CA (1)CA2191088C (en)
CZ (1)CZ292247B6 (en)
DE (2)DE10299030I1 (en)
DK (1)DK0762888T3 (en)
EE (1)EE03423B1 (en)
ES (1)ES2172586T3 (en)
FI (1)FI120236B (en)
GE (1)GEP20002205B (en)
HU (1)HU223473B1 (en)
IL (2)IL113812A (en)
LU (1)LU90987I2 (en)
MD (1)MD1443G2 (en)
NL (1)NL300096I2 (en)
NO (1)NO324528B1 (en)
NZ (1)NZ287335A (en)
PL (1)PL181026B1 (en)
PT (1)PT762888E (en)
SI (1)SI0762888T1 (en)
SK (1)SK283699B6 (en)
TJ (1)TJ392B (en)
UA (1)UA62908C2 (en)
WO (1)WO1995031990A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
RU2834840C1 (en)*2024-07-122025-02-14Федеральное государственное бюджетное образовательное учреждение высшего образования "Ярославский государственный медицинский университет" Министерства здравоохранения Российской ФедерацииMicrosurgical subinginal varicocelectomy method

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6036957A (en)*1990-03-302000-03-14Autoimmune, Inc.Suppression of T-cell proliferation using peptide fragments of myelin basic protein
US7090982B2 (en)1991-10-222006-08-15The Governors Of The University Of AlbertaMethods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US6252040B1 (en)1991-10-222001-06-26The Governors Of The University Of AlbertaPeptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
IL113812A (en)*1994-05-242000-06-29Yeda Res & DevCopolymer-1 pharmaceutical compositions containing it and its use
US5858964A (en)*1995-04-141999-01-12Yeda Research And Development Co. Ltd.Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IL119989A0 (en)*1997-01-101997-04-15Yeda Res & DevPharmaceutical compositions for oral treatment of multiple sclerosis
WO1999041247A1 (en)*1998-02-131999-08-19Autoimmune, Inc.TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
IL141021A0 (en)1998-07-232002-02-10Yeda Res & DevTreatment of autoimmune conditions with copolymer 1 and related copolymers
ES2527760T3 (en)*1998-07-232015-01-29Yeda Research And Development Co., Ltd. Treatment of Crohn's disease with copolymer 1 and polypeptides
AU766498B2 (en)1998-07-232003-10-16President And Fellows Of Harvard College, TheSynthetic peptides and methods of use for autoimmune disease therapies
ES2369642T3 (en)1998-09-252011-12-02Yeda Research And Development Co., Ltd. POLYPEPTIDES RELATED TO COPOLIMER 1 FOR USE AS MOLECULAR WEIGHT MARKERS AND FOR THERAPEUTIC USE.
US6800287B2 (en)*1998-09-252004-10-05Yeda Research And Development Co., Ltd.Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en)1998-09-252003-02-04Yeda Research And Development Co. Ltd. At The Weizmann Institute Of ScienceCopolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000020010A1 (en)*1998-10-022000-04-13Yeda Research And Development Co., Ltd.Alternate day administration of copolymer 1 for treating autoimmune diseases
US7083777B1 (en)1999-04-022006-08-01The Brigham And Women's Hospital, Inc.Immunomodulating polymers
DE60112718T2 (en)*2000-01-202006-06-29Yeda Research And Development Co., Ltd. USE OF COPOLYMER 1 AND RELATED PEPTIDES AND POLYPEPTIDES AND TREATED T CELLS FOR NEUROPROTEKTIVE THERAPY
AU2001238469C1 (en)*2000-02-182006-08-24Yeda Research And Development Co., Ltd.Oral, nasal and pulmonary dosage formulations of copolymer 1
ZA200206457B (en)*2000-02-182003-08-13Yeda Res & DevOral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en)*2000-06-052002-06-20Yong V. WeeUse of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
CA2411536A1 (en)*2000-06-052001-12-13V. Wee YongThe use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
CA2398277C (en)*2000-06-072013-09-03Yeda Research And Development Co. Ltd.The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for protecting cns cells from glutamate toxicity
IL148202A0 (en)*2000-06-202002-09-12Caprion Pharmaceuticals IncCopolymers and methods of treating prion-related diseases
WO2002076503A1 (en)*2000-06-202002-10-03Mayo Foundation For Medical Education And ResearchTreatment of central nervous system diseases by antibodies against glatiramer acetate
IL137460A0 (en)*2000-07-242001-07-24Yeda Res & DevIdentifying antigen clusters for monitoring a global state of an immune system
US20040037828A1 (en)2002-07-092004-02-26Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
SV2003000753A (en)2000-12-052003-06-16Brigham & Womens Hospital USE OF ZWITTERIONIC POLYSACARIDS FOR THE SPECIFIC MODULATION OF IMMUNE PROGRESS
WO2003047500A2 (en)*2001-12-062003-06-12Yeda Research And Development Co. LtdVaccine and method for treatment of motor neurone diseases
KR100442122B1 (en)*2001-07-312004-07-30한국전기연구원Brushless generator with permanent magnet
IL162127A0 (en)*2001-12-042005-11-20Teva PharmaProcess for the measurement of the potency of glatiramer acetate
US20060057107A1 (en)*2001-12-212006-03-16Shaked Ze EvCombination treatment for multiple sclerosis
CA2411786C (en)2002-11-132009-01-27Brantford Chemicals Inc.A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
WO2004060265A2 (en)2003-01-072004-07-22Yeda Research And Development Co. Ltd.Eye-drop vaccine containing copolymer 1 for therapeutic immunization
US8008258B2 (en)*2003-01-212011-08-30Yeda Research And Development Co. Ltd.Cop 1 for treatment of inflammatory bowel diseases
EP1603530A1 (en)*2003-03-042005-12-14Teva Pharmaceutical Industries LimitedCombination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
JP2006522135A (en)2003-03-312006-09-28ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド Zwitterionic immunomodulators for the treatment of asthma and allergies
US20050170004A1 (en)*2003-10-312005-08-04Vered RosenbergerNanoparticles for drug delivery
US20080085269A1 (en)2003-11-122008-04-10Michal Eisenbach-SchwartzVaccine And Method For Treatment Of Neurodegenerative Diseases
AU2004297044B2 (en)2003-12-092010-12-09Yeda Research And Development Co. Ltd.Method and vaccine comprising Copolymer 1 for treatment of psychiatric disorders
WO2005074579A2 (en)*2004-02-022005-08-18Mixture Sciences, Inc.Peptide mixtures with immunomodulatory activity
EP1725603A2 (en)*2004-03-012006-11-29Peptimmune, Inc.Methods and compositions for treatment of autoimmune diseases
JP2007535498A (en)*2004-03-032007-12-06テバ ファーマシューティカル インダストリーズ リミティド Combination therapy with glatiramer acetate and riluzole
US20050260770A1 (en)*2004-04-012005-11-24Cohen Irun RAntigen array and diagnostic uses thereof
JP2007536278A (en)2004-05-072007-12-13ペプチミューン，インコーポレイテッド Method of treating disease using random copolymer
US7655221B2 (en)*2004-05-072010-02-02Peptimmune, Inc.Methods of treating disease with random copolymers
US20060194725A1 (en)*2004-05-072006-08-31James RasmussenMethods of treating disease with random copolymers
WO2006004749A2 (en)2004-06-252006-01-12Id Biomedical Corporation Of QuebecCompositions and methods for treating neurological disorders
EP1797109B1 (en)*2004-09-092016-02-24Yeda Research And Development Co., Ltd.Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
RS52265B (en)2004-09-092012-10-31Teva Pharmaceutical Industries Ltd.Process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid
US8324641B2 (en)*2007-06-292012-12-04Ledengin, Inc.Matrix material including an embedded dispersion of beads for a light-emitting device
WO2006050122A1 (en)*2004-10-292006-05-11Sandoz AgProcesses for preparing glatiramer
AU2005308396B2 (en)*2004-11-292011-06-09Yeda Research And Development Co. Ltd.Induction of neurogenesis and stem cell therapy in combination with Copolymer 1
MX2007009296A (en)*2005-02-022007-09-21Teva PharmaProcess for producing polypeptide mixtures using hydrogenolysis.
SI1848415T1 (en)*2005-02-172013-08-30Teva Pharmaceutical Industries Ltd.Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
US20100167983A1 (en)*2007-10-222010-07-01Teva Pharmaceutical Industries, Ltd.Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
WO2006116602A2 (en)*2005-04-252006-11-02Yeda Research And Development CompanyMarkers associated with the therapeutic efficacy of glatiramer acetate
WO2007081975A2 (en)*2006-01-112007-07-19Teva Pharmaceutical Industries, Ltd.Method of treating multiple sclerosis
US8206726B2 (en)2006-02-062012-06-26The Brigham And Women's Hospital, Inc.Zwitterionic polysaccharides for promotion of immune system maturation and health
WO2007120834A2 (en)2006-04-132007-10-25Peptimmune, Inc.Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
CA2650653C (en)*2006-04-282016-03-29Momenta Pharmaceuticals, Inc.Methods of evaluating glatiramer acetate
KR100831796B1 (en)*2006-05-292008-05-28엘지전자 주식회사 Image display device with time shift function and its reproduction method
CA2656463C (en)2006-06-282015-12-01Yeda Research And Development Co. Ltd.Method of treatment of age-related macular degeneration
EP2046817B1 (en)*2006-07-052009-12-16Momenta Pharmaceuticals, Inc.Improved process for the preparation of copolymer-1
CA2690402A1 (en)2007-06-212008-12-24Momenta Pharmaceuticals, Inc.Copolymer assay
US20090029766A1 (en)*2007-07-262009-01-29Lutnick Howard WAmusement gaming access and authorization point
WO2009016643A1 (en)*2007-07-312009-02-05Natco Pharma LimitedProcess for the preparation glatiramer acetate (copolymer-1)
US9533037B2 (en)2007-10-162017-01-03Declion Holdings LlcMethods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
EP2217250A4 (en)2007-11-092011-01-05California Inst Of Techn IMMUNOREGULATORY COMPOUNDS AND RELATED COMPOSITIONS AND METHODS
MX2010005676A (en)*2007-11-282010-08-06Teva PharmaMethod of delaying the onset of clinically definite multiple sclerosis.
ES2449865T5 (en)2008-04-162022-11-18Momenta Pharmaceuticals Inc Analysis of compositions of amino acid copolymers
BRPI0918718A2 (en)*2008-08-072015-12-01Scinopharm Taiwan Ltd glatiramer acetate synthesis
HUE025042T2 (en)*2008-08-072016-07-28Sigma Aldrich Co LlcPreparation of low molecular weight polylysine and polyornithine in high yield
US9617313B2 (en)2008-12-242017-04-11Synthon BvProcess for purifying a polymer mixture
WO2010115175A1 (en)*2009-04-032010-10-07Momenta Pharmaceticals, Inc.Control of copolymer compositions
US9150609B2 (en)2009-06-042015-10-06Council Of Scientific & Industrial ResearchProcess for the preparation of copolymer-1 using a polymer supported dialkylamine initiator
ES2383347T3 (en)*2009-07-152012-06-20Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and administration procedures
US8920373B2 (en)2009-07-152014-12-30Teva Pharmaceutical Industries, Ltd.Reduced volume formulation of glatiramer acetate and methods of administration
US8691790B2 (en)*2009-07-272014-04-08James Layne BoucherTherapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
PT2405749E (en)2009-08-202013-07-22Yeda Res & DevLow frequency glatiramer acetate therapy
USRE49251E1 (en)2010-01-042022-10-18Mapi Pharma Ltd.Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8377885B2 (en)2010-01-042013-02-19Mapi Pharma Ltd.Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
MX349162B (en)2010-01-042017-07-14Mapi Pharma Ltd *Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof.
EP2523668A1 (en)2010-01-132012-11-21Ramot at Tel-Aviv University LtdTreatment of multiple sclerosis
US8759302B2 (en)2010-03-162014-06-24Teva Pharmaceutical Industries, Ltd.Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
HUE040658T2 (en)2010-04-072019-03-28California Inst Of TechnVehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
CA2797227A1 (en)*2010-04-272011-11-10Dr. Reddy's Laboratories Ltd.Preparation of polypeptides and salts thereof
JP2013530949A (en)2010-05-202013-08-01エル ラウンド ジューン Antigen-specific Tregs and related compositions, methods and systems
KR20130043196A (en)*2010-07-292013-04-29닥터 레디스 래보러토리즈, 인코포레이티드Glatiramer acetate moleuclar weight markers
JP2013541010A (en)2010-10-112013-11-07テバ ファーマシューティカル インダストリーズ リミティド Cytokine biomarkers as predictable biomarkers of clinical response to glatiramer acetate
CA2827275A1 (en)2011-02-142012-09-20Usv LimitedCopolymer-1, process for preparation and analytical methods thereof
EP2699317B1 (en)2011-04-212016-08-10Mapi Pharma LimitedRandom pentapolymer for treatment of autoimmune diseases
WO2012150495A1 (en)2011-05-052012-11-08National Institute Of ImmunologySynthetic peptides and random copolymers for the treatment of autoimmune disorders
WO2013009864A1 (en)2011-07-112013-01-17Momenta Pharmaceuticals, Inc.Structure assessment of heterogeneous polypeptide mixtures
WO2013009885A2 (en)2011-07-112013-01-17Momenta Pharmaceuticals, Inc.Evaluation of copolymer diethylamide
US9539281B2 (en)2011-07-122017-01-10The Brigham And Women's Hospital, Inc.Lipid-containing PSA compositions, methods of isolation and methods of use thereof
US8575198B1 (en)2011-09-072013-11-05Momenta Pharmaceuticals, Inc.In-process control for the manufacture of glatiramer acetate
BR112014008752A2 (en)2011-10-102017-04-25Teva Pharma singular nucleotide polymorphisms useful for predicting the clinical response to glatiramer acetate
WO2013139728A1 (en)2012-03-192013-09-26Synthon BvGlatiramer acetate human monocyte cell-based potency assay
EP2642290A1 (en)2012-03-192013-09-25Synthon BVGlatiramer acetate human monocytic cell line-based potency assay
US20140045740A1 (en)*2012-08-132014-02-13Momenta Pharmaceuticals, Inc.Analysis of glatiramer acetate
MX2015004563A (en)2012-10-102015-07-14Teva PharmaBiomarkers predictive for clinical response for glatiramer acetate.
WO2014060942A2 (en)*2012-10-202014-04-24Mahesh KandulaCompositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
WO2014128079A1 (en)2013-02-192014-08-28Synthon B.V.Glatiramer acetate multidose formulation
EP2774640B1 (en)2013-03-082014-12-31Teva Pharmaceutical Industries, Ltd.Re-useable injector device for syringe
PT2774639E (en)2013-03-082015-01-13Teva PharmaRe-useable injector device for syringe
CN105377308B (en)2013-03-142019-07-26迈兰公司Acetic acid copaxone responds biomarker mRNA efficacy determinations
WO2014173463A1 (en)2013-04-262014-10-30Synthon BvGlatiramer acetate human monocytic cell line-based potency assay
WO2014182966A1 (en)2013-05-102014-11-13California Institute Of TechnologyProbiotic prevention and treatment of colon cancer
CN103265624B (en)*2013-05-272015-04-22成都圣诺生物制药有限公司Method for preparing copaxone
CN104371012A (en)*2013-08-122015-02-25深圳翰宇药业股份有限公司Synthesis method of glatiramer acetate
UY35790A (en)2013-10-212015-05-29Teva Pharma GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE
WO2015061610A2 (en)*2013-10-242015-04-30Mylan Inc.Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
JP2017503169A (en)2013-12-312017-01-26イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド Diagnosis of systemic lupus erythematosus using oligonucleotide antigens
KR20230097209A (en)2014-03-122023-06-30예다 리서치 앤드 디벨럽먼트 캄파니 리미티드Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CN104844697B (en)2014-09-262018-10-23深圳翰宇药业股份有限公司The preparation method of acetic acid copaxone
US9155775B1 (en)2015-01-282015-10-13Teva Pharmaceutical Industries, Ltd.Process for manufacturing glatiramer acetate product
EP3265814B1 (en)2015-03-012020-11-18Immunarray Ltd.Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
WO2016201342A1 (en)2015-06-102016-12-15California Institute Of TechnologySepsis treatment and related compositions methods and systems
CA2997211A1 (en)2015-08-192017-02-23President And Fellows Of Harvard CollegeLipidated psa compositions and methods
EP3147667B1 (en)2015-09-242019-06-12CHEMI S.p.A.Analysis of the molecular weight distribution of complex polypeptide mixtures
EP3170836B1 (en)2015-11-232018-10-24Chemi SPARp-hplc analysis of complex polypeptide mixtures
CN107522774B (en)*2016-06-222021-07-02深圳翰宇药业股份有限公司Real-time control method for piperidine residual quantity in glatiramer acetate preparation process
EP3478300B1 (en)2016-06-302022-08-24Stem Cell Medicine Ltd.Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
EP3484441A4 (en)2016-07-152020-03-18President and Fellows of Harvard CollegeGlycolipid compositions and methods of use
US12097292B2 (en)2016-08-282024-09-24Mapi Pharma Ltd.Process for preparing microparticles containing glatiramer acetate
MX2019001999A (en)2016-08-282019-08-29Mapi Pharma LtdProcess for preparing microparticles containing glatiramer acetate.
HUE062393T2 (en)2016-08-312023-11-28Mapi Pharma LtdDepot systems comprising glatiramer acetate
CA3050086A1 (en)2017-03-262018-10-04Mapi Pharma Ltd.Glatiramer depot systems for treating progressive forms of multiple sclerosis
US11510946B2 (en)2017-05-152022-11-29Stem Cell Medicine Ltd.Treatment of multiple sclerosis with adipose-derived stem cells
CA3062964A1 (en)2017-05-152018-11-22Stem Cell Medicine Ltd.Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
WO2019175869A1 (en)2018-03-122019-09-19Yeda Research And Development Co. LtdTreatment of a heart disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
IL36670A (en)*1971-04-211974-09-10Sela MTherapeutic basic copolymers of amino acids
US4444760A (en)*1983-06-171984-04-24Merck & Co., Inc.Purification and characterization of a protein fibroblast growth factor
JPS6053535A (en)1983-09-021985-03-27Nitto Boseki Co LtdProduction of regular polyaminoacid resin
SU1182051A1 (en)1984-04-281985-09-30Таджикский государственный университет им.В.И.ЛенинаPolytripeptides possessing oenantic selectivity in reactions of hydrolysis of carbobenzoxy-d-1 alanine n-nitrophenyl esters
EP0228448B1 (en)1985-06-181991-08-28Emory UniversityUse of biologically active copolymers for the manufacture of a medicament for stimulating the growth of an animal
DD257174A3 (en)1985-12-201988-06-08Ve Forschungszentrum Biotechno PROCESS FOR PREPARING THE PEPTIDES Z ALA ALA LON P NITRANILIDE OR Z ASP ASP PHE OME WITH METALOPROTEASE
SU1469826A1 (en)1986-05-301995-11-20Институт Высокомолекулярных Соединений Ан СссрCopolymer of l-lysine and l-glutamic acid containing side groups and showing prolonged hypotensive activity and compensatory effect at hemorrhagic shock, and a method of its preparing
US4828706A (en)*1988-03-071989-05-09Spectrum Medical IndustriesProcess for performing a dialysis operation
US4908404A (en)*1988-08-221990-03-13Biopolymers, Inc.Synthetic amino acid-and/or peptide-containing graft copolymers
DE8900366U1 (en)*1989-01-131989-08-03Indag Gesellschaft für Industriebedarf mbH, 69214 Eppelheim Foil bags
CA2009996A1 (en)*1989-02-171990-08-17Kathleen S. CookProcess for making genes encoding random polymers of amino acids
SU1690368A1 (en)1989-07-201995-08-20Институт Высокомолекулярных Соединений Ан СссрStatistic copolymers as low toxic compounds having prolonged hypotensive action and method for their production
DE3930733A1 (en)1989-09-141991-03-28Roehm Gmbh METHOD FOR PRODUCING A COMPLEX MEDICINAL PRODUCT
JP2653255B2 (en)*1990-02-131997-09-17武田薬品工業株式会社 Long-term sustained release microcapsules
WO1993010231A1 (en)*1991-11-121993-05-27E.I. Du Pont De Nemours And CompanyCollagen-like polypeptides
IL113812A (en)*1994-05-242000-06-29Yeda Res & DevCopolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en)*1997-01-102001-04-10Yeda Research And Development Co. Ltd.Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
AU7368798A (en)1997-05-061998-11-27Quanta VisionTissue analysis apparatus
DE60112718T2 (en)*2000-01-202006-06-29Yeda Research And Development Co., Ltd. USE OF COPOLYMER 1 AND RELATED PEPTIDES AND POLYPEPTIDES AND TREATED T CELLS FOR NEUROPROTEKTIVE THERAPY
US6936539B2 (en)*2003-09-242005-08-30Micron Technology, Inc.Antireflective coating for use during the manufacture of a semiconductor device

Cited By (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
RU2834840C1 (en)*2024-07-122025-02-14Федеральное государственное бюджетное образовательное учреждение высшего образования "Ярославский государственный медицинский университет" Министерства здравоохранения Российской ФедерацииMicrosurgical subinginal varicocelectomy method

Also Published As

Publication numberPublication date
HK1008657A1 (en)1999-05-14
CN1152874A (en)1997-06-25
NO324528B1 (en)2007-11-12
US20030064914A1 (en)2003-04-03
WO1995031990A1 (en)1995-11-30
DK0762888T3 (en)2002-05-27
SI0762888T1 (en)2002-08-31
US20050171286A1 (en)2005-08-04
DE10299030I1 (en)2003-01-23
IL113812A0 (en)1995-08-31
HUT75672A (en)1997-05-28
BRPI9507758B1 (en)2021-03-16
IL113812A (en)2000-06-29
US7199098B2 (en)2007-04-03
BR9507758A (en)1997-09-23
JP2003105000A (en)2003-04-09
ATE212857T1 (en)2002-02-15
EE03423B1 (en)2001-06-15
CN1174753C (en)2004-11-10
DE69525340T2 (en)2002-09-19
FI964600A0 (en)1996-11-15
NL300096I2 (en)2003-02-03
PL181026B1 (en)2001-05-31
NO964976D0 (en)1996-11-22
US6362161B1 (en)2002-03-26
IL133890A0 (en)2001-04-30
US6620847B2 (en)2003-09-16
HU9603243D0 (en)1997-01-28
CA2191088C (en)2004-09-28
GEP20002205B (en)2000-08-25
JPH10500955A (en)1998-01-27
UA62908C2 (en)2004-01-15
KR970703154A (en)1997-07-03
EP0762888B1 (en)2002-02-06
DE69525340D1 (en)2002-03-21
EP0762888A4 (en)1997-04-16
NL300096I1 (en)2002-10-01
US5981589A (en)1999-11-09
CZ292247B6 (en)2003-08-13
US5800808A (en)1998-09-01
NZ287335A (en)1999-02-25
EP0762888A1 (en)1997-03-19
PL317331A1 (en)1997-04-01
CN1310673C (en)2007-04-18
US6048898A (en)2000-04-11
US8367605B2 (en)2013-02-05
CN1626238A (en)2005-06-15
FI964600L (en)1996-12-05
US6054430A (en)2000-04-25
AU2602195A (en)1995-12-18
US20070117757A1 (en)2007-05-24
EE9600170A (en)1997-06-16
NO964976L (en)1997-01-23
PT762888E (en)2002-07-31
LU90987I2 (en)2003-02-25
CA2191088A1 (en)1995-11-30
HU223473B1 (en)2004-07-28
ES2172586T3 (en)2002-10-01
SK149396A3 (en)1997-08-06
KR100403750B1 (en)2006-02-13
SK283699B6 (en)2003-12-02
US6342476B1 (en)2002-01-29
US20120077754A1 (en)2012-03-29
MD1443F1 (en)2000-04-30
US6939539B2 (en)2005-09-06
JP3715600B2 (en)2005-11-09
US20040106554A1 (en)2004-06-03
FI120236B (en)2009-08-14
CZ341096A3 (en)1997-06-11
MD1443G2 (en)2000-11-30
US7625861B2 (en)2009-12-01

Similar Documents

PublicationPublication DateTitle
TJ392B (en)Fraction of copolymer-1 and method prodaction of it, composition for the treatment of multiple sclerosis, farmaceutical composition, method for the t reatment of multiple sclerosis.
WO1998007745A3 (en)Compositions and methods for treating infections using analogues of indolicidin
IL126082A0 (en)Compositions for alleviating neuropathic pain comprising prosaposin-derived peptides
MX9703643A (en)Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein.
MX9704030A (en)2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
BG101392A (en)Method of treating diabetes mellitus using kgf
IL106894A0 (en)Dorsal tissue affecting factor and compositions
HU9700826D0 (en)Pharmaceutical compositions against peptic ulcer
DE69429365D1 (en) ANTI-INFLAMMATION COMPOSITION AND METHOD IN WHICH DES-TYR DYNORPHINE AND ANALOGS ARE USED
PL316656A1 (en)Free halophantrin base for use in treating marsh-fever and compositions containing same
BG101232A (en)Bactericides
AU634003B2 (en)4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
GB9320232D0 (en)Alginate wound dressing
EA199800819A1 (en) METHOD OF TREATMENT OF BIPOLAR DISORDER
EP1174439A3 (en)Compositions and methods for treating infections using analogues of indolicidin
WO1998006431A3 (en)Method for treating diabetes
DE68913995D1 (en) COMPOSITION FOR TREATING PROGRESSIVE MYOPIA.
WO1998014567A3 (en)Methods and compositions for inhibiting bacterial growth
IL126157A0 (en)Method for treating excessive aggression
UA15363A (en)Composition for treating open wounds
BR9709007A (en) Use of substituted azaspirane in the treatment of asthma.
[8]ページ先頭
©2009-2025 Movatter.jp